Dengue Vaccine Market Report 2026

The dengue vaccine market size has grown exponentially in recent years. It will grow from $0.51 billion in 2025 to $0.61 billion in 2026 at a compound annual growth rate (CAGR) of 20.2%. The growth in the historic period can be attributed to rising dengue infection rates, limited availability of early vaccines, increased public health burden, growing awareness of mosquito-borne diseases, early government intervention programs.

The dengue vaccine market size is expected to see rapid growth in the next few years. It will grow to $1.16 billion in 2030 at a compound annual growth rate (CAGR) of 17.3%. The growth in the forecast period can be attributed to expansion of immunization programs, increasing investment in vaccine research, rising healthcare spending in endemic countries, growing focus on multi-strain vaccine efficacy, accelerated regulatory approvals. Major trends in the forecast period include rising global focus on dengue prevention, increasing government-led vaccination programs, growing adoption of tetravalent dengue vaccines, expansion of public health funding in endemic regions, rising demand for pediatric immunization solutions.

The increasing number of dengue fever cases is anticipated to drive the growth of the dengue vaccine market in the coming years. Dengue fever is a viral infection transmitted by Aedes aegypti mosquitoes, leading to symptoms such as high fever, headaches, joint pain, and rashes. The rise in dengue cases can be attributed to factors such as climate change, urbanization, insufficient mosquito control, and the evolution of the virus. The dengue vaccine functions by activating the immune system to recognize and fight the dengue virus, reducing the severity of infections and lowering the risk of severe complications, which helps decrease the number of cases and hospitalizations. For example, in May 2024, the World Health Organization, based in Switzerland, reported that dengue cases in the Americas exceeded 7 million in April 2024, up from 4.6 million cases in 2023. Thus, the increasing incidence of dengue fever is propelling the growth of the dengue vaccine market.

Leading companies in the dengue vaccine market are concentrating on clinical trials to develop innovative formulations such as live attenuated vaccines, which aim to provide broad and long-lasting protection against all four dengue virus serotypes. Live attenuated vaccines are created from a weakened form of the virus that cannot cause disease in healthy individuals but stimulates the immune system to build strong, durable immunity, allowing the body to effectively recognize and combat the real virus upon future exposure. For example, in June 2025, Merck & Co. Inc., a US-based pharmaceutical company, launched the MOBILIZE-1 Phase 3 clinical trial to evaluate V181, its investigational live attenuated quadrivalent dengue vaccine. The study plans to enroll approximately 12,000 healthy children and adolescents aged 2 to 17 in dengue-endemic countries across the Asia-Pacific region, including Indonesia, Malaysia, the Philippines, Singapore, Thailand, and Vietnam. The trial is designed as a randomized, double-blind, placebo-controlled study to assess the safety, immunogenicity, and efficacy of a single dose of V181 against all four dengue virus serotypes, regardless of prior dengue exposure. The vaccine targets symptomatic dengue of any severity, including severe cases requiring hospitalization, and aims to provide broad, long-lasting protection to help reduce the global burden of this rapidly spreading mosquito-borne disease.

In February 2024, Takeda Pharmaceutical Company entered into a partnership with Biological E. Limited, a biotechnology and biopharmaceutical company based in India. This collaboration aims to expedite the production and accessibility of the QDENGA (TAK-003) dengue vaccine in endemic regions by increasing manufacturing capacity and providing multi-dose vials to support national immunization initiatives.

Major companies operating in the dengue vaccine market are Merck & Co. Inc., Sanofi Pasteur Limited, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Biological E. Limited, Saint Louis University, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Instituto Butantan, Bharat Biotech Ltd., Panacea Biotec Limited, SABIN Vaccine Institute, Medigen Vaccine Biologics Corporation, Emergex Vaccines Holding Ltd., BioNet-Asia Co. Ltd., Codagenix Inc., KM Biologics Co. Ltd., Chula Vaccine Research Center, Imutex Ltd.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs on vaccine ingredients, biological inputs, and specialized manufacturing equipment have increased production and import costs across developing dengue vaccine markets, particularly impacting regions in Asia-Pacific and Latin America where dengue prevalence is high. Segments such as live attenuated vaccines and nucleic acid-based vaccines face higher supply chain expenses due to tariff-driven delays. However, these tariffs may also encourage domestic vaccine production capabilities, promoting local biomanufacturing growth and reducing long-term import dependency.

The dengue vaccines market research report is one of a series of new reports that provides dengue vaccines market statistics, including dengue vaccines industry global market size, regional shares, competitors with a dengue vaccines market share, detailed dengue vaccines market segments, market trends, and opportunities, and any further data you may need to thrive in the dengue vaccines industry. This dengue vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A dengue vaccine is a biological preparation aimed at preventing dengue fever, a viral disease transmitted by mosquitoes and caused by the dengue virus (DENV). When exposed to the virus in the future, dengue vaccines help stimulate the body's immune system to recognize and combat the dengue virus.

The primary types of dengue vaccines include live attenuated vaccines, chimeric live attenuated vaccines, inactivated vaccines, subunit vaccines, and nucleic acid-based vaccines. Live attenuated vaccines utilize a weakened form of the virus to elicit an immune response, training the body to fight dengue without causing the illness. These vaccines undergo various phases of development, including phase I, phase II, and phase III trials, and treatments associated with dengue may involve diuretics, anti-allergics, blood thinners, among others. They can be administered through different routes, such as oral and parenteral, and are used by a variety of end users, including hospitals, clinics, government institutions, and non-governmental organizations.Asia-Pacific was the largest region in the dengue vaccine market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengue vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dengue vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dengue vaccine market consists of revenues earned by entities by providing treatment such as chlorothiazide, chlorthalidone, hydrochlorothiazide, and fexofenadine. The market value includes the value of related goods sold by the service provider or included within the service offering. The dengue vaccine market also includes sales of diagnostic kits, combination vaccines, clinical trial products, and post-vaccination monitoring tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.